StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.92−0.05 (-0.84%)

Close on Nov 17, 2026Market cap $148.00KP/E –Yield –

AgomAb Therapeutics cash

Cash and short-term investments held at the end of each period.

AgomAb Therapeutics's cash was €86.42M at Dec 31, 2025. For fiscal 2025 it was €86.42M, down 49.6% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025€86.42M-49.6%
FY2024Dec 31, 2024€171.46M+40.1%
FY2023Dec 31, 2023€122.40M+342.4%
FY2022Dec 31, 2022€27.67M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025€86.42M–
Q4 FY2024Dec 31, 2024€171.46M–
Q4 FY2023Dec 31, 2023€122.40M–
Q4 FY2022Dec 31, 2022€27.67M–

More AgomAb Therapeutics figures

See a number that looks wrong?